<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03940001</url>
  </required_header>
  <id_info>
    <org_study_id>ZJCH1903</org_study_id>
    <nct_id>NCT03940001</nct_id>
  </id_info>
  <brief_title>A Study of Sintilimab Plus Chemoradiation Before Surgery for Esophageal Cancer</brief_title>
  <official_title>A Study of Anti-PD-1 Antibody, Sintilimab Plus Chemoradiation Before Surgery for Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the the efficacy and safety of sintilimab in combination
      with chemoradiation before surgery for esophageal cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>unacceptable toxicity</measure>
    <time_frame>1 year</time_frame>
    <description>&quot;Unacceptable toxicity&quot; is defined as any of the following toxicities: &gt;1 episode of grade 3/4 neutropenia or thrombocytopenia &lt;75,000/μL (despite prior dose reduction) during chemoradiation any toxicity that results in &gt;2 week cumulative delay in chemoradiation any toxicity that is attributed to durvalumab which results in a delay of &gt;8 weeks in surgery, i.e. surgery &gt;16 weeks from the end of radiation, for a potentially operable patient any reason that is attributed to durvalumab which leads to death within 30 days of surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pathologic complete response rate, pCR</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>major pahological response, MPR</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological: Sintilimab For weight &lt;60kg, 3mg/kg IV Q3W day 1, and for weight≥60kg, 200mg IV Q3W day 1
Drug: Paclitaxel 50 mg/m^2 IV Q3W day 1, day 8 and day 15
Drug: carboplatin AUC: 2 IV Q3W day 1, day 8 and day 15
Radiotherapy:
1.8 Gy/fraction ×23 fractions Monday to Friday total dose of 41.4 Gy</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>Other Name: (IBI308)</description>
    <arm_group_label>arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin/paclitaxel</intervention_name>
    <description>carboplatin AUC 2/paclitaxel 50 mg/m2 weekly</description>
    <arm_group_label>arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <description>IMRT or VMAT</description>
    <arm_group_label>arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed esophageal squamous carcinoma

          -  18≤age≤75

          -  ECOG PS is 0-1

          -  TanyN+M0 or T3-4NanyM0 tumors

          -  Patients must have surgically resectable disease treatable by esophagectomy, as
             assessed by a thoracic surgeon

          -  No prior chemotherapy,radiotherapy and immunotherapy

          -  Disease must be clinically limited to the esophagus

          -  No esophageal perforation and no active esophageal bleeding

          -  No interstitial pneumonia or history of interstitial pneumonia

          -  FEV1＞1.2L

          -  Adequate organ function defined at baseline as: WBC ≥3,000/ L，ANC ≥1,500/ L，Platelets
             ≥100,000/ L，Hb ≥9 g/dl； Calculated creatinine clearance &gt;40 ml/min using
             Cockcroft-Gault method: Males: Creatinine CL = Weight (kg) x (140 - Age) . (mL/min) 72
             x serum creatinine (mg/dL)Female：Creatinine CL (mL/min) = Weight (kg) x (140 - Age) x
             0.85 72 x serum creatinine (mg/dL)；Total serum bilirubin ≤1.5 mg/dL， AST/ALT ≤2.5×
             upper limit of normal，Mean QT interval corrected for heart rate (QTc) &lt;470 ms
             calculated from 3 ECGs using Frediricia's Correction

          -  Able to provide written informed consent

          -  Subject is willing and able to comply with the protocol for the duration of the study
             including undergoing treatment and scheduled visits and examinations including follow
             up

        Exclusion Criteria:

          -  Previous treatment with chemotherapy, radiotherapy or immunotherapy

          -  Cervical esophageal cancer

          -  Esophageal perforation or active esophageal bleeding

          -  Interstitial pneumonia or history of interstitial pneumonia

          -  Patients with evidence of metastatic disease

          -  Chronic Hepatitis B or C infection (e.g. Hepatitis B surface Ag positive or detectable
             viral load for Hepatitis B or C). Patients with prior evidence of Hepatitis B or C
             without active infection are eligible

          -  Autoimmune diseases (such as systemic lupus erythematosus, rheumatoid rthritis,
             inflammatory bowel disease, autoimmune thyroid disease), but allow the following
             diseases to enter the next stage of screening: type I diabetes, skin diseases without
             systemic treatment (such as vitiligo, psoriasis)

          -  14 days before the first dose, the patient had an active infection that required
             systemic treatment

          -  Inability to understand or may not comply with test requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>chen ming, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Cancer Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>chen qixun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ji yongling, MD</last_name>
    <phone>08613958085251</phone>
    <email>jiyl@zjcc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Chen, M.D.</last_name>
      <phone>0086-571-88122068</phone>
      <email>chenming@zjcc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 4, 2019</study_first_submitted>
  <study_first_submitted_qc>May 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2019</study_first_posted>
  <last_update_submitted>September 5, 2019</last_update_submitted>
  <last_update_submitted_qc>September 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

